Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea

NCT: NCT07600424 · RECRUITING

NCT IDNCT07600424
StatusRECRUITING
Start Date2026-05-23
Completion2028-02-28
SponsorBrigham and Women's Hospital (OTHER)
First posted
Last updated

Brief Summary

A single arm, pilot study among individuals with rosacea and at least moderate flushing or rednesss will be enrolled in a 4-week trial of taVNS. The particicpants will be followed for an additional 4-weeks following the intervention period to evaluate the durability of the results

Frequently Asked Questions

What is Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea?

Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea is a clinical trial registered under NCT07600424. Current status: RECRUITING.

What is the status of NCT07600424?

The current status of NCT07600424 (Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea) is: RECRUITING.

When did Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea start?

Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea started on 2026-05-23.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑